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Abstract
The mucosal immune system identifies and fights invading pathogens, while allowing non-pathogenic organisms to persist.
Mechanisms of pathogen/non-pathogen discrimination are poorly understood, as is the contribution of human genetic
variation in disease susceptibility. We describe here a new, IRF3-dependent signaling pathway that is critical for
distinguishing pathogens from normal flora at the mucosal barrier. Following uropathogenic E. coli infection, Irf3
2/2 mice
showed a pathogen-specific increase in acute mortality, bacterial burden, abscess formation and renal damage compared to
wild type mice. TLR4 signaling was initiated after ceramide release from glycosphingolipid receptors, through TRAM, CREB,
Fos and Jun phosphorylation and p38 MAPK-dependent mechanisms, resulting in nuclear translocation of IRF3 and
activation of IRF3/IFNb-dependent antibacterial effector mechanisms. This TLR4/IRF3 pathway of pathogen discrimination
was activated by ceramide and by P-fimbriated E. coli, which use ceramide-anchored glycosphingolipid receptors. Relevance
of this pathway for human disease was supported by polymorphic IRF3 promoter sequences, differing between children
with severe, symptomatic kidney infection and children who were asymptomatic bacterial carriers. IRF3 promoter activity
was reduced by the disease-associated genotype, consistent with the pathology in Irf3
2/2 mice. Host susceptibility to
common infections like UTI may thus be strongly influenced by single gene modifications affecting the innate immune
response.
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Introduction
Despite significant advances in the understanding of genetic
variation, common infections are often regarded as too complex
for genetic analysis. While single gene defects have a major impact
on host susceptibility to classic infections like malaria [1], the
extent to which susceptibility to diarrhea, respiratory tract and
urinary tract infection (UTI) is genetically controlled remains
unclear. Critical to the understanding of host resistance and
genetic control is the mucosal route of these infections and the
molecular interactions through which mucosal tissues are
perturbed. UTI serve as a particularly useful model to identify
genetic variants contributing to host susceptibility, as innate
immunity controls the antimicrobial defense and molecular
mechanisms of host parasite interaction are understood in great
detail [2,3]. The disease response to uropathogenic Escherichia coli is
initiated through fimbriae-mediated adherence, and the expres-
sion of P fimbriae distinguishes the pathogenic strains from non-
virulent bacteria, which colonize the same mucosal sites.
TLRs control the survival of complex organisms by balancing
protective against destructive forces of innate immunity. During
infection, each TLR recognizes a relatively small number of
ligands, including conserved microbial patterns (PAMPs) [4]. The
horseshoe-shaped, leucine-rich, extracellular TLR domain and its
co-receptors are involved in recognition of proteins, as well as
lipids, carbohydrates and nucleic acids [5,6,7]. At mucosal sites,
where the bulk of microbial challenge occurs, PAMP recognition is
non-functional, however, and does not explain how mucosal TLRs
distinguish pathogenic microbes from members of the normal flora
[8]. Pathogen-specific TLR responses to mucosal pathogens
require receptors that exclusively engage virulence ligands and
signaling pathways that activate a pathogen-specific defense [8].
For example, uropathogenic E. coli adhere to mucosa via
glycosphingolipid receptors for P fimbriae, thereby activating a
TLR4-dependent but LPS/CD14-independent innate immune
response in epithelial cells [9].
Signaling through cell surface sphingolipids involves ceramide,
the membrane anchor and a ubiquitous component of cell
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their biophysical properties and results in the formation of large
ceramide-enriched membrane platforms, clustering receptor
molecules and facilitating signal transduction following receptor
stimulation [12]. Endogenous SMases, activated by many
infectious agents, cleave ceramide from the extracellular choline-
rich domain of sphingomyelin [13,14,15,16,17] and activate the
‘‘ceramide-signaling pathway’’, which is conserved from yeast to
humans [18]. In addition, pathogens that utilize the extracellular
domain of glycosphingolipids as receptors may release ceramide
after bacterial binding, as first described for P-fimbriated,
uropathogenic E. coli [9,17,19]. Ceramide activates a TLR4-
dependent innate immune response [17], similar to infection-
mediated activation, and we have proposed that ceramide acts as a
signaling intermediate between the pathogen-specific receptors
and TLR4 [9,17,19]. The molecular mechanisms in this important
signal transduction need to be identified, however.
UTIs affect .150 million adults each year and about 5% of
children ,12 years of age. Severe kidney infections like acute
pyelonephritis (APN) are accompanied by life-threatening urosep-
sis in about 30% of adults. Children may develop renal scars,
which are associated with long-term morbidity including hyper-
tension, complications of pregnancy, and renal failure if scarring is
extensive. Despite the urgent need, no tools exist at present to
identify children at risk of developing recurrent acute pyelone-
phritis and renal scarring. Host resistance to UTI is controlled by
the innate immune system, through Toll-like receptor (TLR)
activation [8,9,20]. Previous studies have shown that TLR4-
deficient mice develop asymptomatic carriage rather than severe
disease [8,20,21], suggesting that disturbances in TLR4 signaling
may alter the innate immune dependent host defense [22].
This study examined TLR4 activation by ceramide and P
fimbriated E. coli and characterized this signaling pathway. We
propose that ceramide interacts directly with TLR4, activates
TRAM phosphorylation followed by nuclear translocation of
IRF3. Furthermore, we show that IRF3 dependent innate
immunity is essential for the host defense, as Irf3 knockout mice
develop severe kidney infection. Finally, we show that IRF3
promoter polymorphisms are more common in APN prone
patients than in those who become asymptomatic bacterial
carriers. We propose that this pathway offers a model of how
TLR4 may distinguish pathogens from commensals at the mucosal
level, through modification of pathogen recognition receptors,
adaptors and transcription factors.
Results
Increased susceptibility to acute pyelonephritis in Irf3
2/2
mice
In a genetic screen of innate immune effector genes downstream
of TLR4, we identified IRF3 as a major determinant of host
susceptibility. Irf3
2/2 and Irf3
+/+ mice were infected via the
urinary tract mucosal route with the uropathogenic E. coli strain
CFT073 [23]. The Irf3
2/2 mice developed more severe disease
than wild type (wt) Irf3
+/+ mice. Acute mortality was higher (50%
after 24 hours) and bacterial clearance was significantly impaired,
with higher bacterial counts in urine, kidneys and bladders
(Figure 1A, p,0.001). Abscess formation was also more extensive
in Irf3
2/2 than in wt mice (day 7 post-infection, Figure 1B–C,
p,0.001). In Irf3
2/2 mice, abscesses were diffuse, destroying large
tissue areas while in wt mice abscesses were morphologically
distinct from surrounding healthy tissue (Figure 1B).
Renal abscess formation is caused, in part, by an imbalance
between neutrophil recruitment and exit from the tissues [24,25].
The kinetics of early neutrophil recruitment did not differ between
wild type and Irf3
2/2 mice (Figure 1A), but later, neutrophil
recruitment subsided in wt mice but remained elevated in Irf3
2/2
mice. In tissue sections from Irf3
2/2 mice, neutrophils were
detected throughout the abscesses and P-fimbriated bacteria were
interspersed among the neutrophils, as shown by PapG adhesin-
specific antibody detection (Figure 1D, for negative control, see
Figure S1). Wt mice, in contrast, had discrete, neutrophil
aggregates with fewer bacteria. The results suggest that Irf3 is
essential for a functioning innate immune defense against UTI, to
maintain tissue integrity and to clear mucosal E. coli infection.
To examine if the IRF3-dependent immune response discrim-
inates uropathogenic E. coli from non-pathogenic bacteria, we
inoculated wt and Irf3
2/2 mice with the prototypical asymptom-
atic bacteriuria strain E. coli 83972, which lacks functional UTI-
associated virulence factors, including P fimbriae [26,27,28,29].
Both wt and Irf3
2/2 mice cleared infection rapidly, with no
difference in bacterial counts (Figure 1E) and no significant
neutrophil recruitment (data not shown). As P fimbriae are
essential virulence factors, present in up to 100% of E. coli strains
causing urosepsis [30,31], we subsequently examined if P fimbriae
activate the IRF3 pathway. The asymptomatic carrier strain E. coli
83972 was transformed with a chromosomal copy of the pap gene
cluster. We compared disease severity and bacterial counts
between wt and Irf3
2/2 mice infected with E. coli 83972pap.
The Irf3
2/2 mice developed acute, symptomatic disease with
sepsis and had dramatically increased bacterial numbers in
bladders, kidneys and spleens (Figure 1E, p,0.05), compared to
wt mice, which were resistant to infection with E. coli 83972pap.
The results show that the IRF3-dependent response distinguish-
es pathogenic E. coli from non-pathogenic strains and suggest that
the expression of a single virulence factor like P fimbriae enables
the host to recognize a potential pathogen and to activate this
response.
Author Summary
The host immune system must identify pathogens and
defeat them through TLR-dependent signaling pathway
activation, while distinguishing them from commensal
flora. Contrary to current dogma, the host cannot solely
use ‘‘pattern recognition’’ since the microbial molecules
involved in such recognition are present on pathogens
and commensals alike. We identify here a pathogen-
specific mechanism of TLR4 activation and signaling
intermediates in this pathway, leading to IRF3-dependent
transcription of innate immune response genes. We show
in knockout mice that Irf3 deficiency causes severe tissue
pathology and that effector functions controlled by IFNb
are involved. Finally, in highly disease-prone pyelonephritis
patients we found a high frequency of IRF3 promoter
polymorphism compared to asymptomatic bacterial carri-
ers or controls. The polymorphisms influenced promoter
activity in reporter assays, suggesting that they are
functionally important. Urinary tract infections are among
the most common bacterial infections in man, and are a
major cause of morbidity and mortality. A subset of
disease-prone individuals is at risk for recurrent disease,
severe renal dysfunction and end-stage renal disease. At
present, there is no method to identify disease-prone
infants and to prevent future morbidity and renal damage.
The genetic and functional studies described here indicate
that genetic variation in IRF3 influences individual suscep-
tibility to kidney infection and might serve as a new tool
for future risk assessment in this patient group.
Mucosal Pathogen Recognition via TLR4/IRF3
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P fimbriae bind to glycosphingolipid receptors and trigger
ceramide release [9]. To investigate the mechanism of pathogen-
specific TLR4/IRF3 signaling activation, we examined if
ceramide and TLR4 interact after ceramide release from
membrane glycosphingolipids. We treated A498 kidney epithelial
cells with sphingomyelinase (SMase) for one hour, to release
ceramide (r-ceramide) from the extracellular phosphocholine
domain of sphingomyelin [32] (Figure 2A–D). We labeled TLR4
and native ceramide with specific primary antibodies followed by
Alexa fluor-488 (donor) and Alexa fluor-568 (acceptor)-labeled
secondary antibodies, respectively. In unstimulated cells (no
SMase treatment), where ceramide remains bound to sphingomy-
elin, we detected no FRET signal. After SMase treatment, we
recorded a significant FRET signal (Figure 2A–D, 50% FRET-
positive cells compared to 8% for unstimulated cells, p,0.05), with
most of the FRET-positive regions localized in the plasma
membrane. LPS and soluble CD14 (sCD14) stimulation, in
contrast, did not stimulate a FRET signal above background
(p.0.05, compared to unstimulated cells). sCD14 was used, as the
uroepithelial cells lack membrane-bound CD14 and respond
poorly to LPS [33]. These results suggest that ceramide interacts
with TLR4 after release from membrane glycosphingolipids.
To examine the ceramide-induced TLR4 signaling pathway, we
used RNA interference to suppress specific genes (Figure 2E, siRNA
used for transfection are listed in Table S1 in Supporting
Information S1; for knockdown efficiency compared to control
cells transfected with irrelevant siRNA, see Figure S2). First,
suppression of TLR4 expression abrogated the innate immune
response to r-ceramide (p,0.001), confirming that this pathway is
TLR4 dependent. Secondly, TRAM siRNA inhibited the responses
to r-ceramide (p,0.05 compared to the siRNA control). MyD88-
specific siRNA did not alter the ceramide response (p.0.05
compared to the siRNA control) but did reduce the response to
LPS+sCD14 (p,0.05), as did TLR4- and TRAM-specific siRNAs.
To further investigate ceramide-induced TLR4 signaling,
TRAM phosphorylation (TRAM-P) was quantified by confocal
microscopy, using polyclonal phospho-specific anti-TRAM anti-
bodies (Figure 2F–G and Figure S3). We detected an increase in
TRAM-P staining in cells exposed to r-ceramide or exogenous,
water-solubleC6 ceramide; staininghad a granular appearance and
was most intense in the perinuclear area. By Western blot analysis
(Figure 2H), a band corresponding to TRAM-P was increased in
cells exposed to C6 and r-ceramide compared to unstimulated cells
but total TRAM levels were not altered. LPS+sCD14 triggered
weaker TRAM phosphorylation, as shown by confocal microscopy
(p,0.001comparedtor-ceramide)andbyWesternblot.Theresults
indicate that ceramide triggers TRAM phosphorylation more
efficiently than LPS+sCD14. As TRAM phosphorylation was
virtually absent in unstimulated cells, this pathway may need to
be activated by exogenous or endogenous stimuli.
Kinase phosphorylation downstream of ceramide/TLR4
To define signaling downstream of ceramide/TLR4 and
TRAM, we examined kinase phosphorylation, using phosphoar-
rays specific for 46 protein kinases and substrates (Figure 3A).
Ceramide release stimulated the phosphorylation of twelve protein
kinases: p27
T198, eNOS, CREB, Fyn (all 2.3-fold), Hck, PLCc1,
Jun (all 2.1-fold), Pyk2 (2-fold), ERK1/2 and Src (1.9-fold),
RSK1/2/3 (1.8-fold), p27
T157 (1.7-fold), and p53 (1.6-fold).
Antibacterial effectors included eNOS, which regulates nitric
oxide and related antibacterial effector functions [34] and Hck, a
Src-family tyrosine kinase associated with secretory lysosomes in
neutrophils and phagosome-lysosome fusion [35]. A number of the
significantly phosphorylated proteins activate IRF3- and AP1-
dependent transcription. PLCc1 catalyzes the formation of inositol
1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol
4,5-bisphosphate, leading to PKC activation and CREB (cAMP
response element binding) phosphorylation [36,37]. CREB is then
phosphorylated and binds to CBP (CREB-binding protein), which
preferentially associates with phosphorylated IRF3 [38,39],
leading to IRF3. Fyn is a Src family tyrosine kinase implicated
in the activation of PKA, a protein kinase involved in CREB
phosphorylation [40]. Jun in combination with Fos bind to and are
a part of the AP-1 transcription factor complex [41], which
induces the transcription of proinflammatory cytokines. Pyk2
activation is highly correlated with the stimulation of c-Jun N-
terminal kinase (JNK). Identified phosphorylation targets also
included ERKs (ERK1/2, extracellular signal-regulated kinases)
which activate downstream protein kinases and transcription
factors, including IRF3 and AP-1 [42].
CREB phosphorylation in r-ceramide-activated cells was
confirmed by confocal microscopy (Figure 3D, E, p,0.001
compared to control), but was not detected in LPS-stimulated
cells. We obtained similar results using antibodies specific for
phosphorylated Fos (Figure 3D, E). JNK phosphorylation, in
contrast, was similar after r-ceramide and LPS+sCD14 stimulation
(Figure 3D, E), suggesting that JNK signaling was not ceramide-
specific (p,0.001 compared to the control). The results suggest
that ceramide-induced TLR4 signaling causes rapid phosphory-
lation/transcription of proteins involved in IRF3 and AP-1
transcription, including CREB, Fyn, PLCc, MAP kinases,
ERK1/2 and Fos/Jun (Figure S4). LPS+sCD14, in contrast,
caused a weaker phosphorylation response, comprising p27
T198 (2-
fold), eNOS (1.8-fold), PLCc1 (1.7-fold), Pyk2 (1.7-fold), and Jun
(1.6-fold), but not the remaining targets that were phosphorylated
in response to r-ceramide (Figure 3A).
Transcriptional activation in response to ceramide
Innate immune activation in response to ceramide was further
examined by TLR SuperArrays and compared to LPS+sCD14
(Figure 3B, Figure S5). After one hour, five genes in A549 cells had
responded to r-ceramide: Fos (6.5-fold) and Jun (2.1-fold), IL-8
(4.4-fold), IL-6 (2.9-fold) and IL-1a (2-fold). The response showed
a similar, restricted repertoire in A498 carcinoma cells after three
hours (Figure 3C). r-Ceramide upregulated TRAM, Fos and Jun
transcription (10.2-, 2.2- and 2.4-fold, respectively). Ceramide
activated IL-6 transcription (6.2-fold), MAP3K1 and MAP2K3
(5.9- and 2.5-fold), as well as IL-8 and CSF2 transcription levels
(about 3-fold). In contrast, LPS+sCD14 did not significantly
Figure 1. Increased mortality and tissue damage in Irf3
2/2 mice after experimental UTI. Uropathogenic E. coli CFT073 established acute
pyelonephritis more efficiently in Irf3
2/2 (n=11) compared to Irf3
+/+ (n=10) mice. Panel A shows increased mortality (*** p,0.001), bacterial
numbers in urine, kidneys and bladders (** p,0.01, *** p,0.001) and neutrophil influx (*** p,0.001). Geometric means 6 SEMs. Panels B–D show
destruction of renal tissue in Irf3
2/2 mice. Sections were stained with hematoxylin-eosin or specific antibodies (neutrophils=green, NIMP-R14, PapG
adhesin=red, synthetic PapG peptide antibodies and Nuclear Hoechst staining=blue). Scale bar=200 mm. Abscesses are indicated by arrows. Panel
E shows that non-virulent E. coli 83972 are cleared with similar efficiency by wt (n=8) and Irf3
2/2 (n=8) mice. In contrast, a P-fimbriated transformant
E. coli 83972pap, triggers IRF3-dependent disease. Geometric means 6 SEMs (** p,0.01).
doi:10.1371/journal.ppat.1001109.g001
Mucosal Pathogen Recognition via TLR4/IRF3
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After three hours, only IL-8 transcription was higher in response to
LPS+sCD14 than to r-ceramide. The transcriptional profile
confirmed the difference between ceramide and LPS+sCD14
activated cells, consistent with a different transcription factor
usage.
IRF3 translocation to the nucleus in response to
ceramide/TLR4
IRF3 is an interferon regulatory transcription factor and
following TLR4 activation, phosphorylated IRF3 homodimers
translocate from the cytosol to the nucleus [43,44,45,46]. By
confocal microscopy (Figure 4A, C) we observed that r-ceramide
triggered IRF3 translocation to the nucleus (p,0.001 compared to
unstimulated cells, 90 min). We confirmed the results in a human
bladder epithelial cell line (J82, Figure S6A) in which ceramide
release caused rapid IRF3 translocation. In cells exposed to
LPS+sCD14, the nuclear IRF3 translocation was weak (p.0.05
compared to control) and fewer dimers were formed after
exposure to LPS+sCD14. In the bladder epithelial cells, the
IRF3 response to LPS+sCD14 or LPS alone was low.
LPS+sCD14-induced NF-kB p65 translocation, but the NF-kB
response to r-ceramide or C6 ceramide was weak (Figure 4 B, D).
For a broader field of view see Figure S6B.
Signaling through p38 MAPK has previously been shown to
stimulate proinflammatory responses, including IL-8, IL-6 and
TNF [47,48,49]. The activation of MAP3K1 and MAP2K3 by r-
ceramide exposure of A549 cells suggested that this pathway might
be involved upstream of IRF3. Pretreatment of the cells with a p38
inhibitor (SB202190) reduced the IL-8 response to r-ceramide
(Figure 4E) and prevented nuclear translocation of IRF3
(Figure 4F, G). NF-kB p65 translocation was not affected by the
p38 inhibition (Figure 4F, G). The results suggest that ceramide/
TLR4 activates IRF3- rather than NF-kB-dependent transcrip-
tion, and that the IRF3 response involves p38 MAPK-dependent
mechanisms. CREB-phosphorylation was also markedly reduced
after p38 inhibition, as shown by confocal microscopy (.99% in
A498 cells, .50% in A549 cells, Figure 4H) and Western blots
(Figure S7).
Previous work has suggested that the phosphorylation of TRAM
is mediated by PKC-epsilon, which is activated downstream of
TLR4 [50]. Given that PKC-epsilon is also essential for IRF3
activation, this pathway was examined, using the pan-PKC
inhibitor Bisindolylmaleimide II. The inhibitor reduced the
response to PMA, which was used as a PKC dependent, positive
control. In contrast, the response to ceramide was not impaired
(Figure S8).
To further examine the relationship of the ceramide/TLR4
pathway to the classical IRF3 activation pathway, cells were
transfected with TBK1 siRNA and responses were compared to
irrelevant siRNA transfected cells. In parallel, the cells were
transfected with TLR4 and TRAM siRNAs (Knock down
efficiency for TLR4 and TRAM was .90% and 64% for
TBK1, Figure S9). IRF3-P responses to r-ceramide were reduced
by the TLR4 and TRAM siRNAs but were less affected by
suppression of TBK1 expression. The response to LPS+sCD14
showed a similar pattern (Figure S9).
These results suggest that the pathway of IRF3 activation
identified here has several new features, including p38 dependence
and PKC independence. The involvement of TBK1 needs further
study.
Bacterial fimbriae and IRF3 translocation in infected
human renal tubular epithelial cells
To examine if the IRF3 response is triggered in a pathogen-
specific manner involving P fimbriae, we stimulated primary
cultures of human CD14+ renal tubular epithelial cells (HRTEC)
with isogenic P-fimbriated (E. coli S1918pap) or type 1-fimbriated
(E. coli S1918fim) E. coli strains and examined IRF3 by confocal
microscopy. Non-fimbriated E. coli S1918 was used as a control. E.
coli S1918pap induced higher nuclear IRF3 translocation and IRF3
phosphorylation than E. coli S1918, consistent with results in
ceramide-stimulated cells (Figure 5A and Figure S10, p,0.01 for a
broader view). There was less IRF3 translocation in response to E.
coli S1918fim or to the non-fimbriated control E. coli S1918. All
three strains stimulated an NF-kB response, but NF-kB translo-
cation was higher in cells infected with P-fimbriated E. coli
compared to type 1-fimbriated E. coli (Figure 5A, p,0.05).
Uninfected cells showed no evidence of nuclear IRF3- or NF-kB
translocation. The same phenomenon was observed in A498
kidney epithelial cells (Figure S11). In addition, preliminary
Western blot analysis of IRF3P in infected cells suggested that
S1918pap and S1918fim stimulated a higher response than S1918
(Figure S11).
Increased susceptibility to UTI in Ifnb
2/2 mice
IRF3 target gene expression was examined by microarray
analysis. We infected A498 kidney epithelial cells in vitro with
virulent CFT073 or non-pathogenic E. coli (4 hours, 10
8 CFU/ml)
and complementary RNA was hybridized to Illumina whole
genome microarrays. There was a dramatic IFNbresponse to
infection (24-fold above uninfected control cells, $log 2 cut off)
(Figure 5B). By Ingenuity Pathway analysis, we detected significant
activation of several members of the interferon-signaling pathway
such as IFIT1, STAT1 ISG15, IP-10 and IFNAR2. A weaker ISG15
response was observed (1.8-fold above background). By RT-PCR,
a strong IFNb response to r-ceramide was confirmed in human
kidney cells (A498, Figure 5 B and C).
To examine if the effects of IRF3 on host susceptibility are
IFNb-dependent, we infected Ifnb
2/2 mice with E. coli CFT073
Figure 2. Ceramide-TLR4 interactions, adaptors and TRAM phosphorylation. TLR4 and native ceramide were labeled with specific primary
antibodies, followed by Alexa fluor-488 (donor) and Alexa fluor-568 (acceptor)-labeled secondary antibodies, respectively. Acceptor bleaching was
quantified by confocal microscopy, comparing target membrane regions (inset) and cytoplasmic control areas. Panel A shows membrane and
cytoplasmic staining for TLR4 (green) and ceramide (red). Panel B shows recording of donor and acceptor channels, ten times before and after
acceptor bleaching (arrow). The intensity at time 0 was set to 100%. Panel C compared cells exposed to LPS+sCD14 (10+1mg/ml) or r-ceramide
(SMase, 1 U/ml, 1 h). Panel D shows an increase in membrane FRET signals after ceramide release, but not after LPS+sCD14 treatment. Panel E shows
siRNA silencing (black, 72 h transfection) of TLR4, TRAM or MyD88 and resulting inhibition of IL-8 responses in A549 cells, stimulated with SMase (1 U/
ml) or LPS+sCD14 (10+1mg/ml). Cytokine responses (Medians6SEMs $3 experiments) were compared to irrelevant siRNA-transfected cells (grey,
*p ,0.05, **p,0.01, ***p,0.001) which gave significant IL-8 response compared to background level (¤p,0.05, ¤¤p,0.01, ¤¤¤p,0.001). Panel F
shows TRAM phosphorylation (TRAM-P) after r-ceramide, C6 ceramide or LPS+sCD14 exposure (primary polyclonal rabbit-TRAM-P antibodies and
secondary anti-rabbit-Alexa fluor-568-labeled antibodies), for a broader view see Figure S3. Panel G shows TRAM-P fluorescence intensity quantified
with LSM 510 software (mean6SEM, n=30 cells/treatment, * p,0.05, *** p,0.001). (H) TRAM-P expression in A549 cells stimulated for 45 min with
the indicated agonists compared to total TRAM levels (Western blot).
doi:10.1371/journal.ppat.1001109.g002
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(Figure 5E). Bacterial clearance was drastically impaired in Ifnb
2/2
mice compared to wt controls(Figure 5E,p,0.001 between Ifnb
2/2
and wt mice in urine, kidneys and bladders). The Ifnb
2/2 mice also
developed abscesses. Positive spleen cultures confirmed systemic
spread of infection in these mice, which also developed symptomatic
Figure 3. Protein phosphorylation and transcriptomic response to r-ceramide or LPS+sCD14. Panel A shows a phosphoproteomic heat
map of A549 cells stimulated for 60 min with r-ceramide (SMase, 1 U/ml) or LPS+sCD14 (10+1 mg/ml) compared to untreated cells. Fold changes in
protein phosphorylation levels were determined, using the Human Phospho-Kinase Array Kit. Panels B and C show gene expression heat maps of
human epithelial cell RNAs. A549 or A498 cells were stimulated for 1 h or 3 h with r-ceramide or LPS+sCD14. Panels D and E show CREB
phosphorylation (CREB-P) activated by r-ceramide but not by LPS+sCD14 (rabbit anti-human CREB-P primary antibodies). Fos-P activated by r-
ceramide but not by LPS+sCD14 (rabbit anti-human Fos-P primary antibodies). JNK phosphorylation (JNK-P) by r-ceramide and LPS+sCD14 (rabbit
anti-human JNK-P primary antibodies). Fluorescence intensities were quantified with LSM 510 software. Mean 6 SEM, n=60 cells/treatment,
*p ,0.05, *** p,0.001, compared to LPS+sCD14 or ¤ p,0.05, ¤¤¤ p,0.001 compared to unstimulated cells.
doi:10.1371/journal.ppat.1001109.g003
Mucosal Pathogen Recognition via TLR4/IRF3
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suggest that IFNb is activated by infection and that IFNb might
be an essential effector molecule in IRF3-dependent bacterial
clearance.
IRF3 promoter polymorphisms in patients with urinary
tract infection
To examine if UTI susceptibility is associated with differences in
IRF3 promoter efficiency, IRF3 promoter sequence variation was
studied in two highly UTI-prone patient populations. Sample 1
comprised children in southern Sweden, with a consistent UTI
pattern over several years: either severe recurrent kidney infections
(APN; n=21) or asymptomatic carriage of E. coli with no prior
symptomatic infection (primary asymptomatic bacteriuria, ABU,
n=16). These children were identified after prospective, long-term
follow-up of a larger patient group. Sample 2 comprised adults in
western Sweden, with a history of childhood UTI (n=82). They
were enrolled in a prospective study of febrile UTI (APN) in the
1970s and were recently re-evaluated, after about 30 years, to
investigate UTI morbidity and long-term effects on health and
kidney function. Both samples included additional patients who
developed ABU secondary to an APN episode (secondary ABU,
n=16 in sample 1 and n=61 in sample 2). Controls were children
without UTI or related morbidity (n=27) and adult blood donors
(n=62) from the same areas.
DNA sequencing of IRF3 promoters from UTI patients revealed
variation at the 2925 and 2776 positions. SNPs 2925 and 2776
were linked in the study population (r
2=1.0) but the IRF3
genotype varied with UTI severity (Figure 6A–B). Genotype
counts for 2925 and 2776 were in Hardy Weinberg Equilibrium
across both case and control samples apart from the APN group
(x
2=47, p,0.001), indicating effects of genetic drift in the APN
group. We observed significant differences for the two studied
markers between cases and controls in allelic or genotypic models.
In sample 1, most of the APN patients were homozygous for the
two positions (A/A–C/C, 79% vs. 25% in primary ABU,
Figure 6A p=0.0017). The results in APN patients were
confirmed in sample 2, with 75% homozygous and 13%
heterozygous SNPs compared to 53% and 37% in adult controls.
The differences were confirmed when the two samples were
combined, as shown in Figure 6B. Furthermore, the minor allele
frequency was decreased in APN compared to primary ABU
(p=0.0103) and controls (p=0.0239) (Figure 6B). The minor
allele frequency for paediatric UTI patients, adult UTI patients
and the relevant controls are demonstrated in Supplemental Table
S4 in Supporting Information S1.
The IRF3 genotype of the secondary ABU patients resembled
the APN groups in both samples, consistent with their prior APN
episodes.
The acute pyelonephritis-associated promoter SNPs
reduced transcription efficiency
To examine if the IRF3 promoter variation influences
transcription efficiency, we cloned promoters from one patient
with APN and one with ABU into a luciferase reporter vector. We
then changed the APN haplotype at positions 2925, 2776 to the
predominating ABU haplotype (A-C to G-T), or the ABU
haplotype to the APN haplotype (G-T to A-C) by site-directed
mutagenesis. We then transfected A498 human kidney epithelial
cells with the different promoter constructs and determined
luciferase activity (Figure 6C). The promoter was functional in
these cells, resulting in luciferase activity above the vector control.
Transcriptional activity from the APN promoter (A-C) was
about 50% lower compared to the ABU (A-T) promoter
(Figure 6C). This difference could be attributed to the polymor-
phic sites, as the promoter activity increased when the APN A-C
haplotype was mutated to G-T and decreased when the ABU G-T
haplotype was mutated to A-C (p,0.001). This difference was
confirmed by cloning the IRF3 promoters from three additional
APN (A-C) and three ABU (G-T) patients (p=0.001). The results
show that the IRF3 promoter efficiency is reduced by the SNPs
occurring in about 80% of APN patients, consistent with the
human SNPs reducing IRF3 expression and increasing the risk for
APN.
Discussion
IRF3 was originally described as a transcription factor
controlling interferon responses to viral infection [51]. More
recently, the involvement of IRFs in antibacterial defense and
immunoregulation by TLRs has received more attention, since
NF-kB, IRF3 and AP-1 form transcriptional complexes that
regulate innate immune responses in monocytes [52]. The
relevance of IRF3 to human pathology has not been investigated,
however. We show that IRF3 is activated in a pathogen-specific
manner by P-fimbriated, uropathogenic E. coli, through a new
signaling pathway involving TLR4, TRAM, CREB and p38. In
the absence of IRF3, acute morbidity and extensive tissue damage
are dramatically augmented, consistent with the need for this
pathway to maintain a functional antimicrobial defense. Host
susceptibility to common infections like UTI may thus be strongly
influenced by single gene modifications affecting the innate
immune response.
Mucosal pathogens exploit the extracellular domains of
sphingolipids as receptors for AB toxins such as Shiga and cholera
toxin, as well as attachment ligands for Pseudomonas aeruginosa, HIV
gp120 and uropathogenic E. coli [53,54,55]. This study provides
evidence that P-fimbriated E. coli, SMase and exogenous, free
ceramide all activate the IRF3-dependent innate immune
response. Soluble, exogenous ceramide and SMase were used in
parallel in these experiments to ensure that the synthetic, short-
chained form of ceramide and the endogenous, long-chained form
adequately represented the membrane-anchored species in intact
cells. SMase is contaminated by low amounts of LPS, but these
trace amounts were insufficient to activate an innate immune
response in the CD14-negative mucosal cells used in this study
[9,14]. FRET analysis showed that ceramide is approximated to
TLR4 in the cell membrane, suggesting that a direct interaction
with TLR4 and/or the early adaptors trigger this pathway. Such
ceramide-induced TLR4/IRF3 signaling might offer a general
mechanism for host sensing of pathogens that perturb membrane
sphingolipids in mucosal cells.
Figure 4. Nuclear IRF3 translocation in response to ceramide/TLR4. Panels A and C show IRF3 and panels B and D show NF-kB p65
translocation in 70% confluent A549 cells exposed to r-ceramide (SMase (1U/ml), C6 ceramide (30 mg/ml) or LPS+sCD14 (10+1 mg/ml) for 90 min
(mean 6 SEM of 50 cells/sample, *** p,0.001 between different stimulations, ¤¤ p,0.01, ¤¤¤ p,0.001 compared to control). Panel E shows that p38-
MAPK inhibition reduces the IL-8 response to r-ceramide and panels F and G show that p38-MAPK inhibition reduces the nuclear translocation of IRF3
but not NF-kB in A549 cells. Panel H shows that CREB phosphorylation is reduced by p38 inhibition in A549 and A498 cells pre-treated with SB202190
(30 min, 20 mM) and stimulated with r-ceramide (SMase (1 U/ml).
doi:10.1371/journal.ppat.1001109.g004
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resistance against UTI. Panel A shows nuclear translocation of IRF3 and NF-kB in human kidney cells infected with P-fimbriated E. coli (10
9 CFU/ml,
for 90 min). E. coli S1918 was transformed with recombinant plasmids pPIL 110-75 encoding P-fimbriae, (S1918pap) or PKL-4 encoding type 1
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to IRF3 discriminates virulent from commensal bacteria, we
infected Irf3
2/2 mice with a commensal-like E. coli strain from a
patient with asymptomatic bacteriuria. This strain did not trigger a
significant response and was cleared efficiently, suggesting that the
IRF3 pathway was not alerted. In constrast, a P-fimbriated
transformant triggered rapid, septic infection in the Irf3
2/2 but
not in wt mice linking this virulence factor that recognizes
glycosphingolipid surface receptors, to the IRF3-dependent host
response. In contrast, IRF3 was not activated by a type 1
fimbriated isogenic strain, suggesting a preference for glycosphin-
golipid rather than glycoprotein receptors. This does not negate
the previous finding that FimH acts as an immune inducer,
protecting against viral infection associated with TLR4 and type 1
interferon signaling, but suggests that the mechanisms differ [56].
The results confirm the pathogen specificity of the IRF3 response
and the role of P fimbriae as a virulence ligand triggering this
response. As a consequence of this selective IRF3 activation, the
uropathogenic or P-fimbriated, commensal E. coli strains influ-
enced epithelial gene transcription in a pathogen-specific manner.
IRF3 phosphorylation in response to ceramide was controlled
by TLR4 and TRAM, as shown using specific siRNA knock down.
Activation was not TBK1 or PKC dependent, however, suggesting
alternative activation compared to previously described mecha-
nisms of IRF3 activation [50]. A schematic of the identified kinases
and targets is given in supplemental Figure S4. Although this
signaling pathway has not been entirely deciphered, a strong
involvement of TRAM and CREB was detected as well as
involvement of p38 MAPK-dependent events. In this model, IRF3
activation was not controlled by PKC dependent mechanisms,
however. The involvement of TBK1 is not clear, but preliminary
experiments did not provide evidence that TBK1 controlled IRF3
phosphorylation in this pathway. In addition, P-fimbriated E. coli
strains and ceramide significantly activated NF-kB, thus providing
a broad basis for the innate immune response to the intact,
complex pathogen. Importantly, the IRF3 response differed after
LPS+sCD14 stimulation, further suggesting that pathogen recog-
nition and pattern recognition agonists trigger partially different
signaling pathways.
The phenotype of Irf3
2/2 mice predicted that reduced IRF3
expression could also increase human susceptibility to severe kidney
infection. In support of this hypothesis, there were marked promoter
sequence differences between children with ABU or APN in a long-
term prospective study and we confirmed an association of
polymorphisms to disease severity in adult patients who were
followedforabout30yearsaftertheirfirstfebrileUTIepisode.Inthe
past, we haveshownthat genetic variation affecting innate immunity
modifies human UTI susceptibility [2]. Chemokine receptor
expression and neutrophil function are modified by CXCR1
expression, and promoter variants reducing TLR4 expression are
coupled to asymptomatic bacteriuria [22,57,58,59,60]. The present
study adds IRF3 to this short list of polymorphic innate immune
response genes that distinguish asymptomatic carriers from
APN-prone patients.
The human IRF3 promoter has a number of transcription factor
binding sites, including a HOX box, three SP1 sites, NF1, USF,
SRF and IRF1-like site and functional elements are within a 113-
nucletide long fragment, containing one Sp-1 site, the IRF1-like
site, NF1 and HOX box. SNP 2925 is located within this region,
indicating a possible role in promoter efficiency. IRF3 promoter
SNPs were first described in patients with systemic lupus
erythematosus (SLE) [61]. It was speculated that the A-C
haplotype increased IRF3 transcription and that the G-T
haplotype might protect against SLE by reducing type I IFN
production. The effect of the Irf3 deletion on disease susceptibility
in mice suggested, however, that risk might be associated with
reduced, rather than increased, IRF3 function. This idea was
supported by luciferase reporter assays designed to test the IRF3
promoter sequences typical of APN- or ABU-prone individuals.
UTIs are among the most common bacterial infections in man,
and remain a major cause of morbidity and mortality [62,63]. A
subset of disease-prone individuals is at risk for recurrent severe
pyelonephritis and renal dysfunction. Therefore, there is a need to
identify and treat these patients, preferably in infancy, when many
of them experience their first febrile UTI episode. Although
predictive diagnostic tools have been suggested [58,59,60], the
present study identifies IRF3 for the first time as an innate immune
responsegeneinvolvedinUTI.Thus,IRF3maybeanewmolecular
target in the diagnosis of UTI susceptibility, potentially creating
more precise approaches for detection and prevention of severe,
recurrent kidney infection and associated debilitating morbidity.
Methods
Ethics statement
For research involving humans, informed written consent was
obtained from all participants or their parents/guardians. The
study was approved by the Ethics Committee of the medical
faculty, Lund University, Sweden (LU106-02, LU236-99).
All the animal experiments were performed with the permission
of the Animal Experimental Ethics Committee at the Lund
District Court, Sweden (numbers M166-04 and M87-07).
Experimental UTI was performed in a level P2 biohazard
laboratory within the MIG animal facility and was governed by
the following directive, law, ordinance and provisions: Council
Directive EG 86/609/EEC, the Swedish Animal Welfare Act
(Djurskyddslag: 1988:534) and the Swedish Animal Welfare
Ordinance (Djurskyddsfo ¨rordning: 1988 :539). Provisions regard-
ing the use of animals for scientific purposes: DFS 2004:15, DFS
2005::4, SJVFS 2001:91, SJVFS 1991:11.
Reagents
SMase (Staphylococcus aureus), bovine serum albumin, SDS, LPS
(Salmonella typhimurium), C6 ceramide, SB202190 and Bisindolylma-
leimide II were from Sigma Aldrich, St Louis, MO, USA. Soluble
CD14 (sCD14) was from Biometec, Greifswald and IL-8 was
quantified by Immulite 100, Siemens, Germany. Lipofectamine
2000 transfection reagent was from Invitrogen. siRNA downregu-
lation (Supplemental Table S1 in Supporting Information S1) was
validated by qRT-PCR, using primers: TLR4 (Hs00152939,
Applied Biosystems), MyD88 (QT00203490, Qiagen), TRAM
(QT00033341, Qiagen), TBK1 (QT00078393). TBK1 siRNA
fimbriae (S1918fim). Infection increased nuclear staining above background for all three strains. E. coli S1918pap triggered stronger IRF3 and NF-kB
responses than E. coli S1918 or E. coli S1918fim. Quantifications of nuclear fluorescence intensity are given in the table, means 6 SEMs of 30 cells/
sample; for a broader view see Figure S11. Panel B shows IRF3 target gene expression after stimulation of A498 kidney epithelial cells with E. coli
CFT073 (Illumina whole genome microarrays, figure shows fold change above uninfected control cells, $log 2 cut off). Infection stimulated genes in
the IFN pathway and increased the IFNb response. Panel C shows TLR-specific superarray data. Panel D shows the increased susceptibility of Ifnb
2/2
mice to infection with CFT073, compared to wt mice. Bacterial numbers are compared in urine and tissues (Kidneys, bladders and spleens).
doi:10.1371/journal.ppat.1001109.g005
Mucosal Pathogen Recognition via TLR4/IRF3
PLoS Pathogens | www.plospathogens.org 11 September 2010 | Volume 6 | Issue 9 | e1001109Figure 6. Human IRF3 promoter sequencevariationand activity in UTI-pronepatients. Panel A shows the IRF3 promoter polymorphisms (2925
and 2776) in highly selected, UTI-prone pediatric and adult patients compared to healthy controls. The homozygous, A/A, C/C genotype at positions 2925
and2776dominatedinpyelonephritis-pronepatients,whiletheG/A,C/Theterozygousgenotypewasmorecommonintheasymptomaticcarriers.PanelB
presents genotype and allele counts for markers 2925 and 2776 with samples 1 and 2 combined. Panel C shows the IRF3 promoter activity in transfected
human kidney epithelial cells. IRF3 promoter SNPs representing the ABU and APN genotypes were amplified from patient DNA altered by site-directed
mutagenesis and cloned into a luciferase reporter plasmid. The predominating APN genotype (A-C) lowered the luciferase expression levels compared to
the ABU genotype (A-T). Graphs show means of one representative experiment out of three, each done in triplicate.
doi:10.1371/journal.ppat.1001109.g006
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Santa Cruz Biotechnology (USA). Human Phospho-Kinase Array
Kit ARY003 was from R&D Systems, Abingdon, Oxford, UK.
Transcriptome analysis of r-ceramide or LPS+sCD14 activated cells
(1 or 3 hours) was by Superarray (PAHS018, SaBioscience) for 84
TLR signaling pathway genes. IRF3 promoter SNPs were identified
by Pyrosequencing using the PSQ 96 SNP Reagent Kit (Biotage,
Uppsala, Sweden, Supplemental Table S1 in Supporting Informa-
tion S1). Rabbit anti-human TLR4 primary antibodies were from
eBioscience, CA, USA, mouse anti-ceramide primary antibodies,
clone MID 15B4 from ALEXIS Corporation, Lausen, Switzerland.
Rabbit anti-human primary antibodies against CREB-P (Ser 133),
Fos-P (Thr 232), JNK-P (Thr 183/Tyr 185) and IRF3 and mouse
anti-human-NF-kB p65 antibodies from Santa Cruz Biotechnology
(USA), rabbit anti-IRF3-P (Ser 396) antibodies were from Cell
SignalingTechnology.Rabbit anti-human-TRAM-P (raised against
the N-terminal end of the protein, aa 7–21 containing phosphoSer
at aa 16) and TRAM antibodies were from FabGennix Inc., Frisco,
TX, USA, NIMP-R14 rat anti-mouse neutrophil specific antibodies
from Abcam, Cambridge, USA, polyclonal rabbit antiserum raised
against a peptide within the PapG adhesin (CRPSAQ-
SLEIKHGDL) was used to detect P-fimbriated E. coli. Alexa 488
anti-rat IgG, Alexa 568 anti-rabbit IgG, Alexa 568 anti-mouse IgM
and Alexa 488 anti-mouse-IgG secondary antibodies were from
Invitrogen, Eugene, Oregon, USA. Swine anti-rabbit immunoglob-
ulins-HRP secondary antibodies were from DAKO A/S, Glostrup,
Denmark and Santa Cruz Biotechnology (USA). FRET and
fluorescence microscopy was by LSM510 META confocal
microscope (Carl Zeiss, Oberkochen, Germany).
Cell cultures
The human lung adenocarcinoma A549 (ATCC CCL-185) and
kidney carcinoma A498 (ATCC HTB-44) epithelial cell lines were
grown in RPMI 1640 supplemented with 1 mM sodium pyruvate,
1 mM non-essential amino acids, 50 mM/ml gentamicin, and 5%
FBS. Human renal tubular epithelial cells (HRTEC) were isolated
as described [64]. Cells were maintained at 37uC+5% CO2 in a
humidified atmosphere, split weekly and exposed to P-fimbriated,
type I fimbriated or non-fimbriated E. coli, 0.1–1 U/ml of SMase,
freshly prepared C6 ceramide or LPS+sCD14. IL-8 secretion was
quantified by Immulite 100 (Siemens, Bad Nauheim, Germany).
FRET
LSM 510 Meta confocal laser-scanning microscopy was used for
FRET acceptor photobleaching and imaging of epithelial cells.
Cell stimulation/infection was in 8-well chamber slides (LabTek,
Nunc, RPMI+5% foetal calf serum). The cells were first stimulated
with r-ceramide (1U of SMase/ml) or LPS+sCD14 (10+1mg/ml),
fixed with 3.7% formaldehyde and stained with a mouse antibody
specific for native ceramide (sphingosine-trans-D-erythro-2-ami-
no-4-octadecene-1.3-diol) and with a rabbit polyclonal antibody,
specific for the extracellular domain of TLR4 (amino acids 6–169).
Secondary antibodies to TLR4 and free ceramide were conjugated
with Alexa-488 (donor) and Alexa-568 (acceptor), respectively.
FRET efficiency was estimated in percent of fluorescence increase
calculated by: FRET efficiency=((IDA-IDB)/IDA)6100% where
IDA is the donor intensity after bleaching and IDB the donor
intensity before bleaching.
siRNA transfection
A549 human epithelial cells in 24-well plates (TPP) were siRNA
transfected, using Lipofectamine 2000 (Supplemental Table S1 in
Supporting Information S1). Knockdown efficiency was validated
by qRT-PCR. After a 72 h incubation, transfected cells were
stimulated with SMase (1 U/well) or LPS+sCD14 (10+1mg/ml).
Supernatants were collected after 24 h.
RT-PCR array
Total extracted mRNAs were converted to cDNA using RT
2
First Strand Kit (SABioscience Corporation, Fredrick, MA, USA).
The transcriptomic profile of cells exposed to r-ceramide or
LPS+sCD14 was examined using a RT-PCR-based superarray,
containing 84 genes involved in TLR signaling (SABiosciences,
PAHS018). Gene expression levels were calculated by the DCt
method and normalized to five housekeeping genes. RT-PCR was
used to determine the efficiency of siRNA knockdown. The
TaqMan system was used to quantify TLR4 and GAPDH cDNA
and the QuantiTect SYBR Green systems was used to quantify
other genes of interest. cDNA was quantified by RT-PCR using a
Rotor gene 2000 instrument (Corbett Life Science, Sydney,
Australia) and normalized against GAPDH.
Phospho-kinase array
Protein phosphorylation was quantified using the Human
Phospho-Kinase Array Kit (Proteome Prolifer Array, R&D Systems,
Abingdon, Oxford, UK). Protein extracts were prepared from 100%
confluent A549 cells cultured in 6-well plates and treated with 1U/
well SMase or LPS+sCD14 (10+1mg/ml). Untreated cells were used
as control. The signals were detected with the ECL Plus Western
Blotting Detection System (GE Healthcare).
SDS-PAGE and immunoblotting
In order to detect phosphorylated TRAM, A549 cells grown in 6-
well plates were stimulated with 1U/mL SMase, 0.1 mg/mL
LPS+sCD14 (10+1mg/ml), 15 mg/mL C6 (Sigma) or RPMI
medium alone for 45 and 90 min. Cells were lysed in ice-cold
buffer (10 mM HEPES-KOH, 5 mM EDTA, 0.5% Nonidet P-40
and 10 mM KCl, pH 7.9) containing a protease inhibitor mix
(Complete, Roche Diagnostics GmbH, Mannheim, Germany) and
1mM Na3VO4. After 10 min incubation, lysates were centrifuged
for 5 min at 12000 g at 4uC and protein concentrations in the
collected supernatants were quantified using the DC protein assay
kit (Bio-Rad, Hercules, USA). Proteins in the lysates were separated
by SDS-PAGE (4–12% NuPAGE Bis-Tris gels, Invitrogen) on ice
withNuPAGEMESSDSrunning buffer(Invitrogen).Proteins were
transferred to a polyvinylidene difluoride (PVDF) membrane using
NuPAGE transfer buffer (Invitrogen) and the membrane was
probed with phospospecific primary antibodies followed by HRP-
labeled, swine anti-rabbit IgG. Bound antibodies were visualized
with the ECL Plus Western Blotting Detection System.
Native PAGE and immunoblotting
IRF3 dimerization was detected by native PAGE and
immunoblotting. A549 cells cultured in 6-well plates were
stimulated with medium alone, 1 U/mL SMase and 0.1 mg/mL
or LPS+sCD14 (10+1mg/ml), for 90 min. Whole cell lysates in a
buffer containing 50 mM Tris HCl, pH 7.5, 400 mM NaCl, 1mM
EDTA, 1% Nonidet P-40 were separated by electrophoresis on a
7.5% native Tris-glycine gel [65]. Membranes were incubated
with primary antibodies against human IRF3 (Fl-425, Santa-Cruz)
diluted 1:1000 and anti-rabbit IgG-HRP (1:1000). IRF3 mono-
mers and dimers were detected with the ECL Plus Western
Blotting Detection System.
DNA microarray analysis
In brief, A498 cells (n=350000) were seeded in 6-well plates
and infected with CFT073 (10
8 CFU/ml), total RNA was
Mucosal Pathogen Recognition via TLR4/IRF3
PLoS Pathogens | www.plospathogens.org 13 September 2010 | Volume 6 | Issue 9 | e1001109extracted (Trizol, Invitrogen, USA) and cleaned by a Qiagen
RNeasy. RNA was reverse-transcribed to biotin-labeled cRNA
using a TargetAmp Nano-g Biotin-aRNA Labeling kit (Epicentre
Biotechnologies, Madison, USA). Labeled cRNAs were hybridized
onto an Illumina HumanHT-12 Expression Beadchip for 16 hours
at 58uC. The arrays were then washed and stained (Illumina Wash
Protocol) and scanned using a BeadArray Scanner 500GX. The
background-subtracted data were pre-processed to correct nega-
tive and non-significant intensities. Pre-processed data was
normalized using the cross-correlation [66] and genes with a log
fold change of 2 were identified as differentially expressed. Data
was preprocessed using RMA implemented in the free software
packages R and Bioconductor (http://www.r-project.org). For
more details, see Yadav et al.
Differentially expressed genes were categorized using the
Functional Annotation Clustering Tool in the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
[67] and the EASE score (a modified enrichment score derived
from Fisher exact P-value) was used to judge the enrichment. To
further study signaling pathways altered by CFT073, the
differentially expressed genes were submitted for Ingenuity
Pathway Analysis (Ingenuity Systems, Redwood City, CA).
Bacteria and growth conditions
Escherichia coli S1918 [68] (KanR) lacks genes encoding known
adhesins and was used as a recipient strain for recombinant
plasmid pPIL 110-75 (AmpR) carrying the papAD1100 gene
cluster (pap+) [69] or PKL-4 carrying the entire fim gene cluster
from E. coli PC31 (type I+) [68]. The papGX deletion mutant of E.
coli strain 83972 (ABU 83972DpapGX) was generated using the
lambda red homologous recombination technique [70]. Clones
with the reconstituted pap determinant were screened using PCR
and verified by DNA sequencing. Primers used for reconstitution
of a functional pap gene cluster in E. coli 83972 are shown in
Supplemental Table S5 in Supporting Information S1. The
growth rates of the reconstituted mutant strain and the 83972 wild
type strain were shown to be identical. In addition, the ability of
the reconstituted mutant to agglutinate sheep blood erythrocytes
was also confirmed by agglutination assays.
Experimental urinary tract infection (UTI)
Mice were bred at the MIG animal facilities, Lund, Sweden.
Female C57BL/6 wild type or Irf3
2/2 (from T. Taniguichi) and
Ifnb
2/2 (from F. Ivars, Lund University) mice were used at 9–15
weeks. After anesthesia (Isofluorane), mice were infected by
intravesical inoculation with E. coli CFT073 (10
9 CFU in
0.1 mL) through a soft polyethylene catheter (outer diameter
0.61 mm; Clay Adams, Parsippany, NJ, USA). Animals were
sacrificed while under anesthesia, kidneys and bladders were
removed and prepared for hematoxylin-eosin staining or immu-
nohistochemistry. Viable counts in homogenized tissues (Stom-
acher 80, Seward Medical, UAC House, London, UK) were
determined after overnight growth on tryptic soy agar plates at
37uC. Urine samples collected prior to and daily after infection
were cultured and recruited neutrophils were quantified in
uncentrifuged urine by use of a hemocytometer.
Histology and immunostaining
Kidney sections were examined by immunohistochemistry [71].
Tissue sections were dried and permeabilized in 0.2% Triton X-
100, 5% goat normal serum (DAKO) in PBS, incubated with
NIMP-R14 rat anti-mouse neutrophil specific antibodies (1:200)
and a polyclonal rabbit antiserum to the Pap G adhesin (1:200) to
detect P-fimbriated E. coli and to Alexa 488 anti-rat IgG and Alexa
568 anti-rabbit IgG secondary antibodies and nuclei were
counterstained with DAPI (0.05 mM). After mounting, cover-
slipped slides were examined by fluorescence microscopy (AX60,
Olympus Optical, Hamburg, Germany) at the Department of
Pathology, Lund University, Sweden.
Confocal fluorescence immunocytochemistry was performed on
cells grown to 70–80% confluence on 8-well chamber slides. After
stimulation, cells were fixed and permeabilized with 0.25% Triton
X-100, 5% FBS in PBS and incubated with primary antibodies
diluted 1:50 in 5% FBS in PBS overnight at 4uC. Alexa fluor-
labeled secondary antibodies were applied for 1 hour at RT in the
dark. In order to control specific staining of neutrophils and
bacteria, slides were stained with only secondary antibodies (Figure
S1). Slides were covered with mounting medium (M1289, Sigma)
and cover glasses and the cells were examined with a LSM510
META confocal microscope.
UTI-prone patients and pyrosequencing
The IRF3 promoter from patients with UTI or healthy controls
was sequenced (PSQ96, Biotage, Uppsala, Sweden) and examined
for 2925 and 2776 polymorphisms [61]. Genomic DNA was
extracted from heparinized peripheral blood using the QIAamp
DNA Blood midi kit. More detailed descriptions of inclusion
critera and diagnosis are provided in [58,59,72]. The IRF3
promoter SNPs (2925; 2776) were genotyped using Pyrosequen-
cer PSQ 96 after PCR amplification of chromosomal DNA and a
second biotinylated PCR for each SNP (for primers see
Supplemental Table S2 in Supporting Information S1).
Transient transfection and dual luciferase reporter assay
The promoter sequences from extracted chromosomal DNA
derived from APN and ABU patients were PCR-amplified using
the Infusion primers 59 IRF3 NheI and 39IRF3 NcoI (Supple-
mental Table S3 in Supporting Information S1) and Phusion hot
start polymerase according to the manufacturer (Finnzymes Oy,
Finland). Amplicons were introduced by recombination, using the
Infusion cloning technique (Clontech), into a NheI- and NcoI-
cleaved and gel-purified luciferase reporter vector, pGL3 basic
(Promega). The recombinant DNA was transformed into E. coli
and recombinant clones were screened for the presence of cloned
promoter insert. Plasmids of the correct size were further analyzed
by DNA sequencing using the Big Dye terminator v3.1 cycle
sequencing chemistry and ABI capillary sequence.
A quick change Multi Site-directed Mutagenesis kit (Stratagene)
was used according to the manufacturer’s instructions to create the
various IRF3 promoter constructs (Supplemental Table S3 in
Supporting Information S1). 5498 human kidney epithelial cells
were cultured in 24-well plates at a density of 2.5610
5 cells per
well. The cells were transiently transfected with wild type or
mutant IRF3 promoter driven firefly luciferase constructs (pGL3)
together with a constitutively expressed internal control construct
with Renilla luciferase-thymidine kinase promoter (pRL-TK,
Promega) using Fugene HD (Roche) Transfection reagent at 4:2
ratio. Luciferases were measured using the Dual Luciferase
Reporter System Assay (Promega) with a Glomax Integrated
Luminometer (Promega). Firefly luciferase data were normalized
against transfection efficiency of Renilla luciferase and expressed
as a ratio.
Statistics
Student’s t test or Wilcoxon’s rank-sum test were used for paired
comparisons, Mann-Whitney test was applied for unpaired
comparisons. P values below 0.05 were considered to indicate
statistical significance. Deviations from Hardy-Weinberg equilib-
Mucosal Pathogen Recognition via TLR4/IRF3
PLoS Pathogens | www.plospathogens.org 14 September 2010 | Volume 6 | Issue 9 | e1001109rium (HWE) for genotypes at individual loci in patients and
controls, as well as differences in genotype and allele distributions
between groups, were assessed using the x
2 test. Fisher’s exact test
was used where appropriate.
List of ID numbers for genes and proteins of mouse and
humans
Gene ID number for human TLR4 is 7099, human MyD88 is
4615, human TRIF is 148022, human TRAM is 353376, human
TBK1 is 29110, human CREB is 1385, human IRF3 is 3661,
mouse Irf3 is 54131, human IFNB is 3456 and mouse Ifnb is
15977.
Supporting Information
Figure S1 Secondary antibody control of kidney sections
containing neutrophils and P fimbriated E. coli. Hematoxylin/
Eosin staining of abscesses and a corresponding area stained with
only secondary goat anti-rat immunoglobulins, conjugated with
Alexa fluor-488 and secondary goat anti-rabbit immunoglobulins,
conjugated with Alexa fluor-568.
Found at: doi:10.1371/journal.ppat.1001109.s001 (1.78 MB TIF)
Figure S2 qRT-PCR analysis of knockdown efficiency after
siRNA transfection. The knockdown of TLR4, TRAM and
MyD88 expression in A549 cells was confirmed by RT-PCR. The
mRNA levels were coamplified using GAPDH mRNA as an
internal standard. Cells transfected with an irrelevant siRNA (Ctrl)
were used as a control. Suppression of TLR4 mRNA and TRAM
mRNA was more than 90%, MyD88 mRNA was downregulated
by 80%.
Found at: doi:10.1371/journal.ppat.1001109.s002 (0.09 MB TIF)
Figure S3 Broader field of view of TRAM phosphorylation
(TRAM-P) after 30 or 60 minutes of r-ceramide (SMase (1U/ml),
C6 ceramide (30mg/ml) or LPS+sCD14 (0.1+1 mg/ml) exposure
(primary polyclonal rabbit-TRAM-P antibodies and secondary
anti-rabbit-Alexa fluor-568 labelled antibodies).
Found at: doi:10.1371/journal.ppat.1001109.s003 (1.36 MB TIF)
Figure S4 Identified responders in ceramide/TLR4 induced
signalling; a simplified model. P fimbriated Escherichia coli use
glycosphingolipid receptors to adhere to uroepithelial cells.
Binding triggers ceramide release followed by TLR4 and TRAM
activation. Downstream signaling involves MAP kinases, CREB,
IRF3 nad AP-1 (Jun/Fos). CREB and IRF3 phosphorylation is
partly p38 MAPK dependent but not dependent on PKCe and
TBK-1.
Found at: doi:10.1371/journal.ppat.1001109.s004 (1.03 MB TIF)
Figure S5 Genes involved in TLR4 signaling. Panel A shows
A549 epithelial cells, stimulated for 1 h with r-ceramide (SMase,
1U/ml) or LPS+sCD14 (10+1mg/ml). Panel B shows A498
epithelial cells stimulated for 3 hours. Relative gene expression
was analyzed by RT-PCR-based superarray.
Found at: doi:10.1371/journal.ppat.1001109.s005 (0.12 MB PDF)
Figure S6 Panel A shows IRF3 staining in J82 human bladder
epithelial cells. J82 cells were exposed to r-ceramide (SMase (1U/
ml)), LPS (0.1 mg/ml) or LPS+sCD14 (0.1+1 mg/ml) for 90 min
and analyzed as described in figure 4A. N=Nuclear staining.
Panel B shows Nuclear IRF3 translocation in response to
ceramide/TLR4 in A549 cells. IRF3 and NF-kB p65 translocation
in 70% confluent A549 cells exposed to r-ceramide (SMase (1U/
ml), C6 ceramide (30 mg/ml) or LPS+sCD14 (10+1 mg/ml) for
90 min. N=Nuclear staining.
Found at: doi:10.1371/journal.ppat.1001109.s006 (1.98 MB TIF)
Figure S7 r-ceramide induced CREB and IRF3 phosphoryla-
tion in mouse renal tubular cells (MRTEC) was reduced after
treatment with a p38 inhibitor (SB202190). MRTECs were
stimulated for 90 min with r-ceramide (SMase, 1U/ml) or
LPS+sCD14 (0.1+1mg/ml). Blots of whole cell extracts were
stained with phosphospecific rabbit anti-CREB-P- or rabbit anti-
IRF3-P- and HRP-conjugated anti-rabbit antibodies. The western
blot is a representative of 2 experiments.
Found at: doi:10.1371/journal.ppat.1001109.s007 (1.98 MB
TIF)
Figure S8 Interleukin-8 (IL-8) secretion in A549 cells after
treatment with a PKC inhibitor (Bisindolylmaleimide II,
1300 nM) and 24 hours stimulation with r-ceramide (SMase,
2 U/ml), LPS+sCD14 (0.1+1 mg/ml) or PMA (0.01 ng/ml).
Means 6 SEM of two independent experiments. Med=Medium
alone.
Found at: doi:10.1371/journal.ppat.1001109.s008 (0.15 MB
TIF)
Figure S9 Knockdown of TLR4 and TRAM results in
abrogation of the ceramide dependent activation of IRF3
phosphorylation while knock down of TBK-1 does not. Western
blot analysis after siRNA transfection in A549 cells of TLR4,
TRAM or TBK1 siRNA, irrelevant siRNA was used as a control.
The knockdown of TLR4, TRAM and TBK1 genes were
confirmed by RT-PCR. The knockdown efficiency was more
than 90% for TLR4 and TRAM, and 64% for TBK1.
Found at: doi:10.1371/journal.ppat.1001109.s009 (0.33 MB
TIF)
Figure S10 Broader field of view of nuclear translocation of
IRF3 and NF-kB in primary human renal tubular epithelial cells
after stimulation E. coli (N=Nuclear staining, B=Bacteria). The
P-fimbriated strain (E. coli S1918pap) induced higher nuclear IRF3
translocation than non-fimbriated (S1918) and Type 1 fimbriated
(S1918fim) E. coli while NF-kB was translocated in response to all
strains, although slightly more in P-fimbriated E. coli.
Found at: doi:10.1371/journal.ppat.1001109.s010 (0.58 MB
TIF)
Figure S11 Panel A represents confirmatory experiment of data
described in Figure 5A. P-fimbriated E. coli (S1918pap) induces
IRF3 translocation in A498 human kidney epithelial cells more
efficiently than cells stimulated with unfimbriated E. coli (S1918)
and type 1 fimbriated E. coli (S1918fim) N=Nuclear staining.
Panel B - Western blotting showed higher IRF3-P activation in the
S1918pap infected A498 cells.
Found at: doi:10.1371/journal.ppat.1001109.s011 (1.02 MB
TIF)
Supporting Information S1 Tables S1 to S5.
Found at: doi:10.1371/journal.ppat.1001109.s012 (0.31 MB
PPT)
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